NanoViricides Has Received Regulatory Approval for a Phase II Clinical Trial of NV-387 Oral Gummies as a Treatment for Ebola in DR Congo To Fight the Current Largest Ever and Expanding Ebola Outbreak Life Science Investing
Erasca Strengthens R&D Leadership with Appointment of Internationally Recognized Medical Oncologist Charles S. Fuchs, M.D., M.P.H., as President of R&D Life Science Investing
Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update Life Science Investing
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Life Science Investing
AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile Life Science Investing
Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF Life Science Investing
Greenwich LifeSciences Extends Lock-up of Directors and Officers to January 31, 2027 Life Science Investing
AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026 Life Science Investing
NRx Pharmaceuticals, Inc. to Host Conference Call August 10 to Discuss FDA First-Cycle ANDA Review and Commercial Plans Life Science Investing
